Abstract
Background: The prevalence of anticoagulant use has increased in the United States. Medical providers have the responsibility to explain to patients the management of anticoagulant regimens before an invasive procedure. The pharmacologic characteristics of these medications, specifically their half-lives, are important in timing an interruption of anticoagulant therapy.
Objective: The authors review the current guidelines and recommendations for therapeutic interruption of anticoagulants and the involved pharmacologic factors.
Methods: Guidelines and other literature are summarized with discussion on the pharmacology of each medication. Recommendations on how and when to provide bridging for anticoagulants are discussed. Newer oral anticoagulants also are discussed, along with interruption recommendations.
Results: Literature reveals a conservative approach for using bridging when anticoagulation is interrupted because of higher risks of bleeding. Caution is advised when resuming anticoagulant therapy when neuraxial anesthesia is used.
Conclusion: Perioperative healthcare providers need to balance risks and benefits of anticoagulant therapy with its interruption preoperatively.
Keywords: Anticoagulants, bleeding risk, bridging therapy, direct thrombin inhibitors, factor Xa inhibitors, heparin, neuraxial anesthesia, perioperative care, surgery, warfarin.
Graphical Abstract
Current Clinical Pharmacology
Title:Perioperative Management of Anticoagulants
Volume: 12 Issue: 3
Author(s): Joan M. Irizarry-Alvarado*Lynsey A. Seim
Affiliation:
- Division of Consultative and Diagnostic Medicine, Mayo Clinic, Jacksonville, FL 32224,United States
Keywords: Anticoagulants, bleeding risk, bridging therapy, direct thrombin inhibitors, factor Xa inhibitors, heparin, neuraxial anesthesia, perioperative care, surgery, warfarin.
Abstract: Background: The prevalence of anticoagulant use has increased in the United States. Medical providers have the responsibility to explain to patients the management of anticoagulant regimens before an invasive procedure. The pharmacologic characteristics of these medications, specifically their half-lives, are important in timing an interruption of anticoagulant therapy.
Objective: The authors review the current guidelines and recommendations for therapeutic interruption of anticoagulants and the involved pharmacologic factors.
Methods: Guidelines and other literature are summarized with discussion on the pharmacology of each medication. Recommendations on how and when to provide bridging for anticoagulants are discussed. Newer oral anticoagulants also are discussed, along with interruption recommendations.
Results: Literature reveals a conservative approach for using bridging when anticoagulation is interrupted because of higher risks of bleeding. Caution is advised when resuming anticoagulant therapy when neuraxial anesthesia is used.
Conclusion: Perioperative healthcare providers need to balance risks and benefits of anticoagulant therapy with its interruption preoperatively.
Export Options
About this article
Cite this article as:
Irizarry-Alvarado M. Joan*, Seim A. Lynsey , Perioperative Management of Anticoagulants, Current Clinical Pharmacology 2017; 12 (3) . https://dx.doi.org/10.2174/1574884712666170822092709
DOI https://dx.doi.org/10.2174/1574884712666170822092709 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Peculiarities of the Clinical Course of Oxidative Protein and Lipid Modification in Children with Acute Rheumatic Fever
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Cardiovascular Effects of Coumarins Besides their Antioxidant Activity
Current Topics in Medicinal Chemistry Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Statins in Aortic Disease
Current Pharmaceutical Design Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) An Effective Content Based Medical Image Retrieval by Using ABC based Artificial Neural Network (ANN)
Current Medical Imaging Nanostructured Biomaterials for Regenerative Medicine
Current Nanoscience